Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Panobinostat · Farydak, LBH589

Small molecule · Inhibitor of histone deacetylase (HDAC) · developed by Secura

Approved FDA, Feb 2015

What is Panobinostat?

Panobinostat is a histone deacetylase (HDAC) inhibitor that blocks HDAC enzymatic activity at nanomolar concentrations, leading to histone hyperacetylation, chromatin relaxation, cell cycle arrest and apoptosis in transformed cells. It is studied in myelofibrosis, polycythemia vera, graft versus host disease, acute myeloid leukemia and thalassemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Farydak, LBH589
Drug type
Small molecule
Targets
histone deacetylase (HDAC)
Mechanism
Inhibitor of histone deacetylase (HDAC)
Pathways
histone acetylation and chromatin remodeling, cell cycle arrest, apoptosis, angiogenesis (HIF-1alpha and VEGF gene expression)
Therapy area
Oncology
Developer
Secura
In trials of
NVS
FDA status
Approved as Farydak (February 23, 2015), NDA205353 · FDA label
UNII
9647FM7Y3Z

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 27, 2021). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Acute Myeloid LeukemiaGraft Versus Host DiseasePolycythemia VeraPrimary MyelofibrosisThalassemia

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.